[Perspectives in hepatology in the next 2-3 years: what will be clinically relevant? Viral hepatitis].
Friedrich-Rust
M
M
Klinik für Innere Medizin II mit den Schwerpunkten Gastroenterologie, Hepatologie, Endokrinologie, Diabetologie und Ernährungsmedizin, Universitätsklinikum des Saarlandes.
Forestier
N
N
Zeuzem
S
S
D000547:Amantadine / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D005838:Genotype; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006507:Hepatovirus / Q000187:drug effects / Q000235:genetics; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D019384:Nucleic Acid Synthesis Inhibitors; D011480:Protease Inhibitors / Q000627:therapeutic use; D012254:Ribavirin / Q000031:analogs & derivatives / Q000627:therapeutic use; D019562:Viral Load
D000998:Antiviral Agents; D019384:Nucleic Acid Synthesis Inhibitors; D011480:Protease Inhibitors; D012254:Ribavirin; D007372:Interferons; D000547:Amantadine; C026956:taribavirin